Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grant McArthur

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Annals of Surgical Oncology|July 25, 2007
Dermatofibrosarcoma protuberans: recent clinical progressGrant McArthur
Clinical Advances in Hematology & Oncology : H&O|June 8, 2017
The best treatments to use after checkpoint inhibition in melanomaGrant McArthur
Seminars in Oncology|June 4, 2004
Molecularly targeted treatment for dermatofibrosarcoma protuberansGrant McArthur
Hematology/Oncology Clinics of North America|June 2, 2014
Targeted therapies for cutaneous melanomaDamien Kee, Grant McArthur
Current Oncology Reports|April 24, 2016
Cell Cycle Regulation and MelanomaWen Xu, Grant McArthur
Cancer|July 15, 2010
BRAF, a target in melanoma: implications for solid tumor drug developmentKeith T Flaherty, Grant McArthur
Current Opinion in Oncology|January 15, 2015
Cell cycle control as a promising target in melanomaBelinda Lee, Shahneen Sandhu, Grant McArthur
Melanoma Research|May 5, 2011
Review: mucosal melanoma of the head and neckHaim Gavriel, Grant McArthur, Andrew Sizeland, et al.
The Medical Journal of Australia|July 8, 2014
Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanomaMarliese Alexander, James D Mellor, Grant McArthur, et al.
Current Opinion in Immunology|January 15, 2016
Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibitionPeter Kar Han Lau, Paolo A Ascierto, Grant McArthur
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Annals of Surgical Oncology|July 25, 2007
Dermatofibrosarcoma protuberans: recent clinical progressGrant McArthur
Clinical Advances in Hematology & Oncology : H&O|June 8, 2017
The best treatments to use after checkpoint inhibition in melanomaGrant McArthur
Seminars in Oncology|June 4, 2004
Molecularly targeted treatment for dermatofibrosarcoma protuberansGrant McArthur
Hematology/Oncology Clinics of North America|June 2, 2014
Targeted therapies for cutaneous melanomaDamien Kee, Grant McArthur
Current Oncology Reports|April 24, 2016
Cell Cycle Regulation and MelanomaWen Xu, Grant McArthur
Cancer|July 15, 2010
BRAF, a target in melanoma: implications for solid tumor drug developmentKeith T Flaherty, Grant McArthur
Current Opinion in Oncology|January 15, 2015
Cell cycle control as a promising target in melanomaBelinda Lee, Shahneen Sandhu, Grant McArthur
Melanoma Research|May 5, 2011
Review: mucosal melanoma of the head and neckHaim Gavriel, Grant McArthur, Andrew Sizeland, et al.
The Medical Journal of Australia|July 8, 2014
Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanomaMarliese Alexander, James D Mellor, Grant McArthur, et al.
Current Opinion in Immunology|January 15, 2016
Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibitionPeter Kar Han Lau, Paolo A Ascierto, Grant McArthur
Pageof 7